Promising Remission with Reduced Bevacizumab and Pembrolizumab Dosage in a Patient with AT-rich Interaction Domain 1A Mutated Ovarian Clear-cell Carcinoma Refractory to Chemotherapy

Promising Remission with Reduced Bevacizumab and Pembrolizumab Dosage in a Patient with AT-rich Interaction Domain 1A Mutated Ovarian Clear-cell Carcinoma Refractory to Chemotherapy

Patients with ovarian clear-cell carcinoma have limited treatment choices, because they are resistant to the standard chemotherapeutic agents used in ovarian cancer. The phase II KEYNOTE-100 trial revealed that pembrolizumab monotherapy demonstrated a 15.8% objective response in patients with ovaria...

Full description

Saved in:
Bibliographic Details
Main Authors: Cheng-Wei Huang, Ruo-Han Tseng
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2024-01-01
Series:Journal of Cancer Research and Practice
Subjects:
angiogenesis inhibitor
at-rich interaction domain 1a
immune checkpoint inhibitor
ovarian clear-cell carcinoma
Online Access:https://journals.lww.com/10.4103/ejcrp.eJCRP-D-23-00035
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://journals.lww.com/10.4103/ejcrp.eJCRP-D-23-00035

Similar Items